Abstract : Metformin is a biguanide used as first line treatment of type 2 diabetes mellitus. When metformin alone is unable to control glycaemic status properly then additional drug needs to be added. Some of the additional drugs reduce primarily fasting blood sugar (FBS) and some reduce post prandial blood sugar (PPBS). Voglibose and Teneligliptin are primarily capable of reducing PPBS. In this background the present study was planned for comparative study of voglibose and Teneligliptin to reduce PPBS ongoing metformin monotherapy. It was a hospital based longitudinal interventional study among patients attending General Medicine OPD of ICARE medical college with uncontrolled hyperglycemia and whose HbA1c was above 7 but upto 10% and PPBS above 200mg/dl. One group of patients were given Voglibose 0.3mg TDS and another group of patients were given Teneligliptin 20mg BD in addition to previous dose of metformin. After 8 weeks of starting additional drug again PPBS level was assessed for each patient. It was found that mean PPBS level at the beginning was 296 mg/dl for voglibose group and 288mg/dl for Teneligliptin group. There was no significant difference between these two. After 8 weeks of therapy the mean PPBS level of voglibose group was significantly higher than Teneligliptin group. However both groups showed significant reduction of PPBS as compared to starting. The study highlights the ability to reduce PPBS is more with Teneligliptin 20mg BD than Voglibose 0.3mg TDS.

Keyword : PPBS, Voglibose, Teneligliptin